Complete Dose Comparison & Switching Guide
Understanding Wegovy and Mounjaro Doses When Switching
Switching between Wegovy and Mounjaro doses requires careful consideration of their different mechanisms and dose escalation schedules. Wegovy (semaglutide) follows a structured 16-week escalation from 0.25mg to the maintenance dose of 2.4mg weekly, while Mounjaro (tirzepatide) escalates from 2.5mg to up to 15mg weekly over a similar timeframe. The key difference lies in their receptor activity—Wegovy targets GLP-1 receptors exclusively, whereas Mounjaro activates both GIP and GLP-1 receptors as a dual agonist. This fundamental difference means there's no direct 1:1 dose conversion between the medications.
When considering a switch, your prescriber will evaluate your current response, side effect profile, and individual tolerance. Many patients switch from Mounjaro to Wegovy due to cost considerations, as Wegovy often presents better value at maintenance doses. Others switch from Wegovy to Mounjaro seeking potentially enhanced efficacy from the dual receptor mechanism. The transition typically involves stopping one medication and beginning the other at its initial starter dose, though your prescriber may recommend a modified approach based on your treatment history and current dose level.
Wegovy and Mounjaro Doses: Pricing Comparison & Savings
The cost difference between Wegovy and Mounjaro doses can be significant over time. Wegovy pricing at EverydayMeds starts at £79.99 for the 0.25mg starter dose with new customer code FIRST40, progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Returning customers can use code DOSE25 for continued savings. Our Getting Started bundles like the Intro Duo (0.25mg & 0.5mg) cost £169.99, providing convenient dose progression. The Ultimate Stability Trio offers three months of 2.4mg maintenance supply for £649.99, ensuring treatment continuity.
Many patients find switching to Wegovy can reduce their monthly medication costs by £50-80 compared to alternative suppliers. Our Consistency bundles provide excellent value for patients staying on the same dose—for example, Consistency 1mg (×2 pens) costs £209.99. The transparent pricing structure helps you budget effectively throughout your dose escalation journey. Both medications are prescription-only medicines requiring clinical assessment, but the potential cost savings make Wegovy an attractive option for long-term weight management alongside a reduced-calorie diet and increased physical activity.
Clinical Evidence for Wegovy and Mounjaro Doses
The STEP clinical trial programme demonstrates Wegovy's efficacy across different doses. In STEP 1, patients taking Wegovy alongside diet and exercise achieved an average weight loss of approximately 15% at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 2 showed patients with type 2 diabetes achieved around clinically studied weight loss, while STEP 3 demonstrated approximately clinically studied weight loss when combined with intensive behavioural therapy.
The SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events (HR 0.80) with Wegovy treatment. This evidence supports the medication's role beyond weight management in cardiovascular risk reduction. When comparing these results to Mounjaro's SURMOUNT trials, both medications show substantial efficacy, though direct comparisons aren't appropriate due to different trial designs and populations. Your prescriber can help interpret how these clinical findings apply to your individual situation when considering switching between these prescription-only medicines.
How Wegovy Works at Different Doses
Wegovy functions as a GLP-1 receptor agonist, mimicking the natural incretin hormone GLP-1 that regulates appetite and glucose metabolism. At each dose level, from the starter 0.25mg through to maintenance 2.4mg, semaglutide binds to GLP-1 receptors in the brain's appetite control centres, promoting feelings of satiety and reducing food cravings. The mechanism involves slowing gastric emptying, which helps you feel fuller for longer after meals, and directly influencing hypothalamic appetite regulation. Unlike Mounjaro's dual receptor approach, Wegovy's single-target mechanism provides focused GLP-1 activity. The dose escalation schedule allows your body to gradually adapt to increased semaglutide levels, minimising side effects while optimising therapeutic benefits. Higher doses generally correlate with greater appetite suppression and weight loss potential, though individual responses vary considerably between patients.
Ordering Process for Wegovy and Mounjaro Doses
Switching between Wegovy and Mounjaro doses through EverydayMeds follows a streamlined process designed for convenience and safety. Begin with our 3-minute online clinical assessment, which evaluates your medical history, current medications, weight management goals, and reasons for switching between treatments. Our UK-qualified prescribers (GPhC #9012878) review your assessment within 3 working days, or opt for express 24-hour review if needed urgently. The prescriber will determine the appropriate starting dose for your new medication, whether transitioning from Mounjaro to Wegovy or vice versa. Once approved, your medication ships via next-day delivery using cold-chain temperature-controlled packaging to maintain potency. This seamless process eliminates the hassle of finding new pharmacy providers when switching medications, providing continuity of care throughout your weight management journey.
Storage Differences: Wegovy and Mounjaro Doses
Understanding storage requirements becomes crucial when switching between Wegovy and Mounjaro doses, as they differ significantly in room temperature stability. Wegovy pens can remain at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, offering superior travel convenience and flexibility. In contrast, Mounjaro maintains stability for only 21 days at room temperature, requiring more careful storage planning. Both medications should be stored in the refrigerator at 2-8°C before first use and come in easy-to-use FlexTouch injection pens. The extended room temperature stability of Wegovy makes it particularly suitable for patients with busy lifestyles, frequent travel, or limited refrigeration access. When switching medications, ensure proper disposal of unused pens and maintain the cold chain during delivery to preserve medication efficacy throughout your dose transition.
Personalised Switching Strategies for Wegovy and Mounjaro Doses
Developing an effective switching strategy between Wegovy and Mounjaro doses requires understanding your specific treatment goals and tolerance profile. Patients experiencing gastrointestinal side effects with one medication may find better tolerance with the other, though both can cause similar adverse effects during dose escalation. Cost-conscious patients often switch to Wegovy for its competitive pricing structure and bundle options that reduce long-term expenses. Some patients switch due to supply chain considerations, ensuring uninterrupted treatment by having access to both medication options through one pharmacy provider.
Your switching timeline should account for the washout period and gradual dose escalation required with the new medication. Most prescribers recommend starting the new medication at its lowest dose regardless of your previous dose level, allowing your body to adapt to the different receptor activity profile. This approach minimises side effects and optimises long-term adherence. The ability to access both Wegovy and Mounjaro through EverydayMeds means seamless transitions without changing pharmacy providers, maintaining consistent service quality and prescription management throughout your weight management journey.
Start Your Switch Today: Wegovy and Mounjaro Doses
Ready to explore switching between Wegovy and Mounjaro doses? Visit our weight loss collection at https://everydaymeds.co.uk/collections/weight-loss to compare options and start your clinical assessment. New customers can use code FIRST40 for optimal pricing, while returning customers apply DOSE25 at checkout for continued savings. Our prescribers provide personalised guidance on dose selection and switching strategies, ensuring your transition is both safe and effective. Both medications are prescription-only medicines requiring proper clinical oversight, and our GPhC #9012878 registered pharmacy ensures compliance with UK regulations throughout your treatment. Don't let medication costs or availability concerns interrupt your weight management progress—explore your switching options today and discover potential savings while maintaining therapeutic effectiveness.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
